Tegeo is an oral chemotherapy drug that was first approved for advanced gastric cancer, but later it was found to be effective for head and neck tumors, breast cancer, non-small cell lung cancer, colorectal cancer, pancreatic cancer, biliary tract cancer, etc. It is still widely used in clinical practice. The dosage should be calculated according to the patient’s body surface area. Generally, it should be taken once a day after breakfast and dinner, and a cycle of 14 days or 21 days or 28 days should be taken orally continuously, with repeated application for 4-6 cycles. Adverse reactions are still relatively mild compared to intravenous infusion of chemotherapy drugs, nausea and vomiting are relatively rare, but there are certain side effects that need attention, like bone marrow suppression. In the clinical application, the patient’s blood count should be reviewed weekly to see the degree of decline in white blood cells, red blood cells and platelets. Hepatotoxicity is rare.